2020 SFORL指南:复发性腮腺多形性腺瘤的管理

2020-08-13 法国耳鼻喉科学会 Eur Ann Otorhinolaryngol Head Neck Dis . 2020 Aug 13

2020年8月,法国耳鼻喉科学会(SFORL)发布了复发性腮腺多形性腺瘤的管理指南,主要内容涉及年龄和复发风险,其他复发的危险因素,一期手术的影响,病理学,和周围性面瘫,术后放疗等。

中文标题:

2020 SFORL指南:复发性腮腺多形性腺瘤的管理

英文标题:

Guidelines of the French Society of Otorhinolaryngology-Head and Neck Surgery (SFORL), part II: Management of recurrent pleomorphic adenoma of the parotid gland

发布机构:

法国耳鼻喉科学会

发布日期:

2020-08-13

简要介绍:

2020年8月,法国耳鼻喉科学会(SFORL)发布了复发性腮腺多形性腺瘤的管理指南,主要内容涉及年龄和复发风险,其他复发的危险因素,一期手术的影响,病理学,和周围性面瘫,术后放疗等。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2020 SFORL指南:复发性腮腺多形性腺瘤的管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=2c8d01c001956698, title=2020 SFORL指南:复发性腮腺多形性腺瘤的管理, enTitle=Guidelines of the French Society of Otorhinolaryngology-Head and Neck Surgery (SFORL), part II: Management of recurrent pleomorphic adenoma of the parotid gland, guiderFrom=Eur Ann Otorhinolaryngol Head Neck Dis . 2020 Aug 13, authorId=0, author=, summary=2020年8月,法国耳鼻喉科学会(SFORL)发布了复发性腮腺多形性腺瘤的管理指南,主要内容涉及年龄和复发风险,其他复发的危险因素,一期手术的影响,病理学,和周围性面瘫,术后放疗等。, cover=https://img.medsci.cn/2020824/1598277618815_2020535.jpg, journalId=0, articlesId=null, associationId=804, associationName=法国耳鼻喉科学会, associationIntro=null, copyright=0, guiderPublishedTime=Thu Aug 13 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年8月,法国耳鼻喉科学会(SFORL)发布了复发性腮腺多形性腺瘤的管理指南,主要内容涉及年龄和复发风险,其他复发的危险因素,一期手术的影响,病理学,和周围性面瘫,术后放疗等。</p> </div> </div> </div>, tagList=[TagDto(tagId=17938, tagName=腮腺)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=30, categoryName=耳鼻咽喉科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=17938, guiderKeyword=腮腺, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2972, appHits=87, showAppHits=0, pcHits=711, showPcHits=2885, likes=0, shares=2, comments=7, approvalStatus=1, publishedTime=Mon Aug 24 22:22:04 CST 2020, publishedTimeString=2020-08-13, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Mon Aug 24 22:00:29 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 05:26:54 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 SFORL指南:复发性腮腺多形性腺瘤的管理.pdf)])
2020 SFORL指南:复发性腮腺多形性腺瘤的管理.pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=974900, encodeId=eeca9e4900ea, content=学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/faa5f8ddffb44fd99e0c6f83cd6936db/42f1f7c3f10846daa28959538c26e9c7.jpg, createdBy=c59d5529126, createdName=kurtchen, createdTime=Sat Jun 19 16:43:38 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888606, encodeId=84fb88860635, content=mark, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epaOKZMG8XyvYlDbeibtTNWoibGPaF8RaoZWZfXLZ24ic2zu8C3xciaOEgmCWx8eoK2bMtQ0qhgTcBOEQ/132, createdBy=faf92453297, createdName=z834416508, createdTime=Sat Sep 26 22:43:23 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814143, encodeId=6b4d814143ca, content=标记一下 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 17:40:29 CST 2020, time=2020-08-27, status=1, ipAttribution=)]
    2021-06-19 kurtchen

    学习!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=974900, encodeId=eeca9e4900ea, content=学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/faa5f8ddffb44fd99e0c6f83cd6936db/42f1f7c3f10846daa28959538c26e9c7.jpg, createdBy=c59d5529126, createdName=kurtchen, createdTime=Sat Jun 19 16:43:38 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888606, encodeId=84fb88860635, content=mark, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epaOKZMG8XyvYlDbeibtTNWoibGPaF8RaoZWZfXLZ24ic2zu8C3xciaOEgmCWx8eoK2bMtQ0qhgTcBOEQ/132, createdBy=faf92453297, createdName=z834416508, createdTime=Sat Sep 26 22:43:23 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814143, encodeId=6b4d814143ca, content=标记一下 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 17:40:29 CST 2020, time=2020-08-27, status=1, ipAttribution=)]
    2020-09-26 z834416508

    mark

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=974900, encodeId=eeca9e4900ea, content=学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/faa5f8ddffb44fd99e0c6f83cd6936db/42f1f7c3f10846daa28959538c26e9c7.jpg, createdBy=c59d5529126, createdName=kurtchen, createdTime=Sat Jun 19 16:43:38 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888606, encodeId=84fb88860635, content=mark, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epaOKZMG8XyvYlDbeibtTNWoibGPaF8RaoZWZfXLZ24ic2zu8C3xciaOEgmCWx8eoK2bMtQ0qhgTcBOEQ/132, createdBy=faf92453297, createdName=z834416508, createdTime=Sat Sep 26 22:43:23 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814143, encodeId=6b4d814143ca, content=标记一下 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 17:40:29 CST 2020, time=2020-08-27, status=1, ipAttribution=)]
    2020-08-27 ms4000002082197205

    标记一下 学习了

    0